| http://www.w3.org/ns/prov#value | - I think we certainly believe that it is appropriate to be flexible in the approach to products that add value, particularly in more serious diseases and, certainly, oncology drug development and HIV drug development certainly are good examples of that, and we believe that the development of agents for resistant infections clearly falls into that area.
|
